Cerebrolysin for vascular dementia.

We reported dichotomous outcomes as risk ratio (RR) with 95% CI. We assessed the strength of the available evidence using the GRADE approach. MAIN RESULTS: We identified six randomised controlled trials with a total of 597 participants that were eligible for inclusion in the 2013 review. No new studies were eligible for inclusion in this update. Participants in the included studies, where dementia severity was reported, had mild to moderate severity of vascular dementia (four trials). The included studies tested varying doses and duration of Cerebrolysin treatment. Follow-up ranged from 15 days to three years. Five of included studies were conducted in China (three studies), Russia (one study), and Romania (one study), while relevant information of other study was unclear. Where details of funding were available, all studies were supported by the pharmaceutical industry (three studies). Cognitive function was measured using the Mini-Mental State Examination (MMSE) or Alzheimer's Disease Assessment Scale Cognitive Subpart, extended version (ADAS-cog+). Combining the MMSE and ADAS-cog+ data (three studies, 420 people), there was a beneficial effect of Cerebrolysin (SMD 0.36, 95% CI 0.13 to 0.58; very low-quality evidence). Global function was measured by Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC+) or Investigator's Clinical Global Impression (CGI). We assessed response rates on these measures (the proportion of participants with a CIBIC+ ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research

Related Links:

ConclusionsThis study provides information about Aβ plaque burden, tau tangle burden, and neurodegeneration in cognitively unimpaired persons at three levels of genetic risk for AD. Unimpaired APOE ϵ4 HMs can be studied before their 70s to evaluate the understanding of factors, processes, and interventions involved in the predisposition to and prevention of AD, and after their 70s, to discover factors, processes, and interventions involved in the resilience or resistance to and prevention of AD.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
Irene Taylor Brodsky's doc reveals her deaf son's triumph and her deaf dad's Alzheimer's challenges ... "If you told my dad 50 years ago that there would be this tool that would allow him to hear, ...
Source: AARP.org News - Category: American Health Source Type: news
The bacteria in our bodies affect our minds. Cell biologist Sim Singhrao explains how improved oral hygiene, diet and exercise can stave off dementia
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
This study may provide a new strategy for developing novel drugs to treat AD. PMID: 31816602 [PubMed - as supplied by publisher]
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
ConclusionsSignificant variability of regional cardiac123I-MIBG uptake is common in cases with normal planar cardiac uptake. Heterogeneity of regional uptake appears non-specific and unlikely to aid in the diagnosis of Lewy body disease.
Source: Journal of Nuclear Cardiology - Category: Nuclear Medicine Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Many patients with cognitive impairment have anxiety or depression, but standard treatments are difficult for people with memory issues.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Mental Health and Disorders Depression (Mental) Alzheimer ' s Disease Memory Dementia Psychology and Psychologists Elderly Weill Cornell Medicine your-feed-healthcare Source Type: news
CONCLUSIONS: This study did not support an association between statin use and diagnostic conversion but suggested a possible association between statin use and cognitive change in EMCI. Additional randomized clinical trials of statins may be warranted in the prodromal EMCI stage of AD. PMID: 31806426 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
EARLY PREDICTION OF ALZHEIMER'S DISEASE DEMENTIA BASED ON BASELINE HIPPOCAMPAL MRI AND 1-YEAR FOLLOW-UP COGNITIVE MEASURES USING DEEP RECURRENT NEURAL NETWORKS. Proc IEEE Int Symp Biomed Imaging. 2019 Apr;2019:368-371 Authors: Li H, Fan Y, Alzheimer’s Disease Neuroimaging Initiative Abstract Multi-modal biological, imaging, and neuropsychological markers have demonstrated promising performance for distinguishing Alzheimer's disease (AD) patients from cognitively normal elders. However, it remains difficult to early predict when and which mild cognitive impairment (MCI) individuals will convert to...
Source: Proceedings - International Symposium on Biomedical Imaging - Category: Radiology Tags: Proc IEEE Int Symp Biomed Imaging Source Type: research
CONCLUSION: The low agreement between amyloid PET/CT and previous clinical and instrumental assessments that we found in our study suggests that the amyloid PET/CT provides additional and early information. To perform an early and differential diagnosis of AD could have a great impact on the patient's management and cost of care in order to perform the correct therapeutic interventions and to allow family members to manage adequately the patient's demanding care. PMID: 31802055 [PubMed - in process]
Source: Hellenic Journal of Nuclear Medicine - Category: Nuclear Medicine Tags: Hell J Nucl Med Source Type: research
More News: Alzheimer's | Brain | China Health | Databases & Libraries | Dementia | General Medicine | Men | Neurology | Romania Health | Russia Health | Study